Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732

• DOI: 10.1677/jme.1.02165
• Publication Date: 2007-04-19T13:25:17Z
• Authors: Yoo Mee Kim; Juan Ji An; Yong-Jun Jin; Yumie Rhee; Bong Soo Cha; Hyun Chul Lee; Sung-Kil Lim
• Keywords: Taste aversion

The systemic treatment with angiogenesis inhibitor has been shown to result in weight reduction and adipose tissue loss various models of obesity. To verify the mechanism CKD-732 (TNP-470 analog) against obesity, we evaluated CKD-732’s peripheral central anti-obesity effects. was injected subcutaneously (s.c.) for 7 days animal intracerebroventricularly (i.c.v.) arcuate nucleus (ARC) lesion mice, ob / normal littermates. Modulation hypothalamic neuropeptide mRNAs after i.c.v. injection ARC mice A conditioned taste aversion (CTA) performed using lithium chloride (LiCl) as a positive control agent Long–Evans Tokushima Otsuka fatty (OLETF) rats. As result, s.c. reduced cumulative food intake body significantly both treated obese (e.g. 114.8 ± 13.4 g vs 170.7 20.6 g, 7.9 0.5% decrease 0.3 2.2% decrease; OLETF rat versus rat, P < 0.01 respectively) non-obese models. Epididymal mesenteric fat pads, size adipocytes were decreased single but not Unexpectedly, altered by injection. also induced dose-dependent CTA comparable LiCl injection, which is commonly used produce CTA. In conclusion, causes significant appetite reduction, possibly decreasing adiposity directly inducing anorexia, partly explained These results should be carefully verified assess utility an drug.